FACC MD - Milestone Pharmaceuticals Chief Officer
| MIST Stock | USD 1.99 0.12 6.42% |
Insider
FACC MD is Chief Officer of Milestone Pharmaceuticals
| Age | 60 |
| Address | 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6 |
| Phone | 514 336 0444 |
| Web | https://www.milestonepharma.com |
Milestone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3309) % which means that it has lost $0.3309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3375) %, meaning that it created substantial loss on money invested by shareholders. Milestone Pharmaceuticals' management efficiency ratios could be used to measure how well Milestone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2024. Return On Capital Employed is likely to drop to -0.94 in 2024. At this time, Milestone Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 468 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 6.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| McDavid Stilwell | Coherus BioSciences | 52 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Rebecca Sunshine | Coherus BioSciences | 61 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Dan Williams | Inhibikase Therapeutics | N/A | |
| MBA MD | Spero Therapeutics | 43 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Roger Rush | Inhibikase Therapeutics | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Susan Kalled | Compass Therapeutics | 61 | |
| Vered MBA | Compass Therapeutics | 53 | |
| Jeff York | Seres Therapeutics | N/A | |
| Joern Aldag | Hookipa Pharma | 65 | |
| JeanPaul MD | Inventiva Sa | N/A | |
| Grey Wilkinson | Oncolytics Biotech | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.33 |
Milestone Pharmaceuticals Leadership Team
Elected by the shareholders, the Milestone Pharmaceuticals' board of directors comprises two types of representatives: Milestone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Milestone. The board's role is to monitor Milestone Pharmaceuticals' management team and ensure that shareholders' interests are well served. Milestone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Milestone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Guy Rousseau, SVP Management | ||
| FACC FAHA, Chief Board | ||
| Jeffrey Nelson, Chief Officer | ||
| Anita Holz, VP Affairs | ||
| Amit Hasija, CFO Development | ||
| Roshan Girglani, Vice Marketing | ||
| Joseph MBA, President CEO | ||
| Kim Fox, Vice Communications | ||
| FACC MD, Chief Officer | ||
| Jeff Nelson, Chief Officer | ||
| Lorenz Muller, Chief Officer | ||
| Kimberly Sheehan, VP HR | ||
| Philippe MBA, Strategic Founder |
Milestone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Milestone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 83.72 M | ||||
| Shares Outstanding | 53.33 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 57.01 % | ||||
| Number Of Shares Shorted | 438.27 K | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 4.42 X | ||||
| Price To Sales | 91.95 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.